title: Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children.
abstract: OBJECTIVE
  We assessed the immunogenicity and safety of a combination measles, mump, rubella, and varicella vaccine (MMRV) (ProQuad [Merck & Co, Inc, West Point, PA]) administered to healthy children concomitantly with a pneumococcal 7-valent conjugate vaccine (PCV-7) (Prevnar [Pfizer, Philadelphia, PA]).
  
  
  METHODS
  Healthy 12- to 15-month-old children who lacked vaccination and clinical histories for measles, mumps, rubella, varicella, and zoster but had written documentation of receipt of a 3-dose primary series of PCV-7 were randomly assigned in a 2:1:1 ratio to receive either the MMRV and PCV-7 (group 1), PCV-7 followed 6 weeks later by MMRV (group 2), or MMRV followed 6 weeks later by PCV-7 (group 3). The primary safety analysis was 56 days (28 days after each visit). Immunogenicity was evaluated 6 weeks after each vaccination.
  
  
  RESULTS
  A total of 1027 children were enrolled (group 1: 510; group 2: 258; group 3: 259). For all 3 groups, the antibody response rate was ≥96.8% for measles, mumps, and rubella, ≥88.0% for varicella-zoster virus, and ≥98.3% for all of the 7 Streptococcus pneumoniae serotypes. The immune responses to all antigens present in MMRV and PCV-7 were similar whether administered concomitantly or sequentially. The incidence of local and systemic adverse experiences (AEs) was comparable between group 1 and groups 2 and 3 combined. No vaccine-related serious AEs were reported.
  
  
  CONCLUSIONS
  Concomitant administration of the MMRV and PCV-7 is highly immunogenic and generally well tolerated. Similar immune responses between the groups support concomitant administration of the MMRV and PCV-7 to healthy children 12 to 15 months of age.
authors: aPalmetto Pediatrics, North Charleston, SC, USA.
authors: Michael
authors: M
authors: Leonardi
authors: Kenneth
authors: K
authors: Bromberg
authors: Roger
authors: R
authors: Baxter
authors: Julie L
authors: JL
authors: Gardner
authors: Stephanie
authors: S
authors: Klopfer
authors: Ouzama
authors: O
authors: Nicholson
authors: Michael
authors: M
authors: Brockley
authors: James
authors: J
authors: Trammel
authors: Vicky
authors: V
authors: Leamy
authors: Wendy
authors: W
authors: Williams
authors: Barbara
authors: B
authors: Kuter
authors: Florian
authors: F
authors: Schödel
mesh_terms: D005260:Female; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007223:Infant; D008297:Male; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*
chemical_list: D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D022242:Pneumococcal Vaccines